Treatment of depression associated with the menstrual cycle: Premenstrual dysphoria, postpartum depression, and the perimenopause

Dialogues in Clinical Neuroscience

Volumn 4, Issue 2, 2002, Pages 177-191

  Freeman, Ellen W ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antidepressant; Depression; Estrogen; Gonadal hormone; Perimenopause; Postpartum depression; Premenstrual syndrome; Treatment

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BUSERELIN; CALCIUM; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DESOGESTREL; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; GESTAGEN; LEUPRORELIN; MAPROTILINE; NEFAZODONE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PROGESTERONE; PYRIDOXINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIBOLONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

APPETITE DISORDER; ARTICLE; BEHAVIOR; BREAST FEEDING; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIARRHEA; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE ACTION; HUMAN; INSOMNIA; INVOLUTIONAL DEPRESSION; LETHARGY; LIBIDO DISORDER; MENSTRUAL CYCLE; META ANALYSIS; MOOD; MOOD DISORDER; NAUSEA; ORGASM DISORDER; PREMENSTRUAL DYSPHORIC DISORDER; PREVALENCE; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; PUERPERAL DEPRESSION; RISK ASSESSMENT; SEROTONINERGIC TRANSMISSION; SEXUAL DYSFUNCTION; TREATMENT INDICATION; UTERUS CANCER; VERTIGO; WATER RETENTION;

EID: 0038669206     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (173)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
2. Burke KC, Burke JD, Jr, Rae DS, et al. Comparing age at onset of major depression and other psychiatric disorders by birth cohorts in five US community populations. Arch Gen Psychiatry. 1991,48:789-795.
3. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry. 1998;44:839-850.
4. Bloch M, Schmidt PJ, Danaceau M, Murphy J, Nieman L, Rubinow DR. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry. 2000;157:924-930.
5. Endicott J, Amsterdam J, Eriksson E, et al. Is premenstrual dysphoric disorder a distinct clinical entity? J Womens Health Gend Based Med. 1999;8:663-679.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
7. Singh BB, Berman BM, Simpson RL, Annechild A. Incidence of premenstrual syndrome and remedy usage: a national probability sample study. Altern Ther Health Med 1998;4:75-79.
8. Campbell EM, Peterkin D, O'Grady K, Sanson-Fisher R. Premenstrual symptoms in general practice patients: prevalence and treatment. J Reprod Med. 1997;42:637-646.
9. Angst J, Sellaro R, Stolar M, Merikangas KR, Endicott J. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand. 2001;104:110-116.
10. Ramcharan S, Love EJ, Fick GH, Goldfien A. The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors. J Clin Epidemiol. 1992;45:377-392.
11. Deuster PA, Adera T, South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med. 1999;8:122-128.
12. Yonkers KA. The association between premenstrual dysphoric disorder and other mood disorders. J Clin Psychiatry. 1997;58(suppl 15):19-25.
13. Halbreich U, Bergeron R, Freeman E, Stout A, Cohen L. Intermittent luteal phase dosing of sertraline effective in PMDD. Int J Neuropsychopharmacol. 2000;3(suppl 1):S248.
14. Endicott J, Halbreich U. Clinical significance of premenstrual dysphoric changes. J Clin Psychiatry. 1988;49:486-489.
15. Eriksson E. Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. Int Clin Psychopharmacol. 1999;14(suppl 2):S27-S33.
16. Eriksson E, Andersch B, Ho HP, et al. Premenstrual dysphoria: an illustrative example of how serotonin modulates sex-steroid-related behavior. CNS Spectrums. 2001;6:141-149.
17. Kendler KS, Karkowski LM, Corey LA, Neale MC. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry. 1998;155:1234-1240.
18. Freeman EW, Rickels K, Sondheimer SJ, et al. Differential response to antidepressants in women with premenstrual syndrome: a randomized controlled trial. Arch Gen Psychiatry. 1999;56:932-939.
19. Freeman EW, Sondheimer SJ, Polansky M, Garcia-Espagna B. Predictors of response to sertraline treatment of severe premenstrual syndromes. J Clin Psychiatry. 2000;61:579-584.
20. Brzezinski AA, Wurtman JJ, Wurtman RJ, Gleason R, Greenfield J, Nader T. d-Fenfluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression. Obstet Gynecol. 1990;76:296-300.
21. Rickels K, Freeman E, Sondheimer S. Buspirone in treatment of premenstrual syndrome. Lancet. 1989;4:777.
22. Rubinow DR, Roy-Byrne P, Hoban MC, Gold PW, Post RM. Prospective assessment of menstrually related mood disorders. Am J Psychiatry. 1984;141:684-686.
23. Hart WG, Coleman GJ, Russell JW. Assessment of premenstrual symptomatology: a re-evaluation of the predictive validity of self-report. J Psychosom Res. 1987;31:185-190.
24. Ensom MH, Chong E, Carter D. Premenstrual symptoms in women with premenstrual asthma. Pharmacotherapy. 1999;19:374-382.
25. Chandler MH, Schuldheisz S, Phillips BA, Muse KN. Premenstrual asthma: the effect of estrogen on symptoms, pulmonary function, and beta 2-receptors. Pharmacotherapy. 1997;17:224-234.
26. Silberstein SD. Hormone-related headache. Med Clin North Am. 2001; 85:1017-1035.
27. Rosciszewska D. Analysis of seizure dispersion during menstrual cycle in women with epilepsy. Monogr Neural Sci. 1980;5:280-284.
28. McLeod DR, Foster GV, Hoehn-Saric R, Svikis DS, Hipsley PA. Family history of alcoholism in women with generalized anxiety disorder who have premenstrual syndrome: patient reports of premenstrual alcohol consumption and symptoms of anxiety. Alcohol Clin Exp Res. 1994;18:664-670.
29. Marks JL, Hair CS, Klock SC, Ginsburg BE, Pomerleau CS. Effects of menstrual phase on intake of nicotine, caffeine, and alcohol and nonprescribed drugs in women with late luteal phase dysphoric disorder. J Subst Abuse. 1994;6:235-243.
30. Choi SH, Kang SB, Joe SH. Changes in premenstrual symptoms in women with schizophrenia: a prospective study. Psychosom Med. 2001;63:822-829.
31. Rojansky N, Halbreich U, Zander K, Barkai A, Goldstein S. Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol Obstet Invest. 1991;31:146-152.
32. Ashby CR Jr, Carr LA, Cook CL, Steptoe MM, Franks DD. Alteration of 5-HT uptake by plasma fractions in the premenstrual syndrome. J Neural Transm (Gen Sect). 1990;79:41-50.
33. Taylor DL, Matthew RJ, Ho BT, Wienman ML. Serotonin levels and platelet uptake during premenstrual tension. Neuropsychobiology. 1984;12:16-18.
34. Rapkin AJ, Edelmuth E, Chang LC, Reading AE, McGuire MT, Su TP. Whole-blood serotonin in premenstrual syndrome. Obstet Gynecol. 1987;70:533-537.
35. Rapkin AJ, Chang LC, Reading AE. Tryptophan loading test in premenstrual syndrome. J Obstet Gynecol. 1989;10:140-144.
36. Menkes DB, Coates DC, Fawcett JP. Acute tryptophan depletion aggravates premenstrual-syndrome. J Affect Disord. 1994;32:37-44.
37. Steinberg S, Annable L, Young SN, Liyanage N. A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria. Biol Psychiatry. 1999;45:313-320.
38. FitzGerald M, Malone KM, Shuhua L, et al. Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder. Am J Psychiatry. 1997;154:556-558.
39. Su TP, Schmidt PJ, Danaceau M, Murphy DL, Rubinow DR. J Clin Endocrinol Metab. 1997;82:1220-1228.
40. Dimmock PW, Wyatt KM, Jones PW, Shaughn O'Brien PM. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet. 2000;356:1131-1136.
41. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med. 1995;332:1529-1534.
42. Wood SH, Mortola JF, Chan YF, Moossazadeh F, Yen SS. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet Gynecol. 1992;80:339-344.
43. Menkes DB, Taghavi E, Mason PA. Fluoxetine treatment of severe premenstrual syndrome, BMJ. 1992;305:346-347.
44. Ozeren S, Corakci A, Yucesoy I, Mercan R, Erhan G. Fluoxetine in the treatment of premenstrual syndrome. EurJ Obstet Gynecol Reprod Biol. 1997;73:167-170.
45. Pearlstein TB, Stone AB, Lund SA. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol. 1997;17:261-266.
46. Su TP, Schmidt PJ, Danaceau MA, et al. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology. 1997;16:346-356.
47. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. JAMA. 1997;278:983-988.
48. Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry. 1998;59:76-80.
49. Jermain DM, Preece CK, Sykes RL, Kuehl TJ, Sulak PJ. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study. Arch Fam Med. 1999;8:328-332.
50. Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry. 1997;58:399-402.
51. Eriksson E, Hedberg A, Andersch B, Sundblad C. The SRI paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology. 1995;12:167-176.
52. Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol. 1998;18:390-398.
53. Freeman EW, Rickels K, Yonkers KA, Kunz NR, McPherson M, Upton GV. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2001;98:737-744.
54. Sundblad C, Modigh K, Andersch B, et al. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand. 1992;85:39-47.
55. Sundblad C, Hedberg M, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology. 1993;9:133-145.
56. Freeman EW, Rickels K, Sondheimer SJ, Denis A, Pfeifer S, Weil S. Nefazodone in the treatment of premenstrual syndrome: a preliminary study. J Clin Psychopharmacol. 1994;14:180-186.
57. Freeman EW, Rickels K, Sondheimer SJ. Fluvoxamine for premenstrual dysphoric disorder: a pilot study. J Clin Psychiatry. 1996;57(suppl 8):56-59.
58. Altshuler LL, Cohen LS, Moline ML, Kahn DA, Carpenter D, Docherty JP. The Expert Consensus Guideline Series: treatment of depression in women. 2001. Postgrad Med. 2001;(March):1-116.
59. Kennedy SH, Eisfeld BS, Dickens SE, Bacciochi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline and venlafaxine. J Clin Psychiatry. 2000;61:276-281.
60. Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology. 1993;9:133-145.
61. Freeman EW, Rickels K, Arredondo F, Kao LC, Pollack SE, Sondheimer SJ. Full or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacology. 1999;19:3-8.
62. Judge R, Brown E, Miner C, Dillon J. Intermittent fluoxetine dosing in premenstrual dysphoric disorder. Arch Womens Ment Health. 2001;3(suppl 2):1-116. Abstract 0161.
63. Yonkers KA, Barnett LK, Carmody T, Rush AJ. Serial discontinuation of SSRI treatment for PMDD. Biol Psychiatry. 1998;43:1S-133S.
64. Pearlstein TB, Stone AB. Long-term fluoxetine treatment of late luteal phase dysphoric disorder. J Clin Psychiatry. 1994;55:332-335.
65. Elks ML. Open trial of fluoxetine therapy for premenstrual syndrome. South Med J. 1993;86:503-507.
66. Freeman EW, Rickels K, Sondheimer SJ. Course of premenstrual syndrome symptom severity after treatment. Am J Psychiatry. 1992;149:531-533.
67. Schmidt PJ, Nieman LK, Danaceau MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338:209-216.
68. Brown CS, Ling FW, Andersen RN, et al. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol. 1994;84:779-786.
69. Freeman EW, Sondheimer SJ, Rickels K. Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull. 1997;33:303-309.
70. Hammarback S, Bäckström T. Induced anovulation as treatment of premenstrual tension syndrome: a double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand. 1988;67:159-166.
71. Hussain SY, Massil JH, Matta WH, et al. Buserelin in premenstrual syndrome. Gynecol Endocrinol. 1992;6:57-64.
72. Leather AT, Studd JWW, Watson NR, Holland EFN. The treatment of severe premenstrual syndrome with goserelin with and without "addback" estrogen therapy: a placebo-controlled study. Gynecol Endocrinol. 1999;13:48-55.
73. Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined used of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab. 1991;71:252-257.
74. Mezrow G, Shoupe D, Spicer D, Lobo R, Leung B, Pike M. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril. 1994;62:932-937.
75. Di Carlo C, Palomba S, Tommaselli GA, Guida M, Di Spiezio Sardo A, Nappi C. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil Steril. 2001;75:380-384.
76. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res. 1992;36:257-266.
77. Bäckström T, Hansson-Malmström Y, Lindhe BA, Cavalli-Björkman B, Nordenström S. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception. 1992;46:253-268.
78. Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med. 2001;10:561-569.
79. Walker A, Bancroft J. Relationship between premenstrual symptoms and oral contraceptive use: a controlled study. Psychosom Med. 1990;52:86-96.
80. Sveindóttir H, Bäckström T. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand. 2000;79:405-413.
81. Tiemstra JD, Patel K. Hormonal therapy in the management of premenstrual syndrome. J Am Board Fam Pract. 1998;11:378-381.
82. Magos AL, Brincat M, Studd JWW. Treatment of the premenstrual syndrome by subcutaneous oestradiol implants and cyclical oral norethisterone: placebo-controlled study. BMJ. 1986;292:1629-1633.
83. Watson NR, Savvas M, Studd JWW, Garnett T, Baber RJ. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet. 1989;2:730-732.
84. Smith RNJ, Studd JWW, Zamblera D, Holland EFN. A randomised comparison over 8 months of 100 μg and 200 μg twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol. 1995;102:475-484.
85. Maddocks S, Hahn P, Moller F, Reid RL. A double-blind placebo-controlled trial of progesterone vaginal suppositories in the treatment of premenstrual syndrome. Am J Obstet Gynecol. 1986;154:573-581.
86. Freeman E, Rickels K, Sondheimer SJ, Polansky M. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome. JAMA. 1990;264:349-353.
87. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double-blind trial of oral progesterone, alprazolam and placebo in treatment of severe premenstrual syndrome. JAMA. 1995;274:51-57.
88. Berger CP, Presser B. Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study. Obstet Gynecol. 1994;84:379-385.
89. Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam: a controlled study. Arch Gen Psychiatry. 1990;47:270-275.
90. Smith S, Rinehart JS, Ruddock VE, et al. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol. 1987;70:37-43.
91. Rickels K, Freeman, EW, Sondheimer SJ. Buspirone in treatment of premenstrual syndrome. Lancet. 1989;1:777.
92. Schmidt PJ, Grover GN, Rubinow DR. Alprazolam in the treatment of premenstrual syndrome: a double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1993;50:467-473.
93. Dennerstein L, Morse C, Burrows G, Brown J, Smith M. Alprazolam in the treatment of premenstrual syndrome. In: Dennerstein L, Fraser I, eds. Hormones and Behavior. New York, NY: Elsevier Science Publishing; 1986:175-182.
94. Pearlstein T, Steiner M. Non-antidepressant treatment of premenstrual syndrome. J Clin Psychiatry. 2000;61(suppl 12):22-27.
95. Thys-Jacobs S, Starkey P, Bernstein D, et al. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Am J Obstet Gynecol. 1998;179:444-452.
96. Wyatt KM, Dimmock PW, Jones PW, Shaughn O'Brien PM. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ. 1999;318:1375-1381.
97. Stevinson C, Ernst E. Complementary/alternative therapies for premenstrual syndrome: a systematic review of randomized controlled trials. Am J Obstet Gynecol. 2001;185:227-235.
98. den Tonkelaar I, te Velde ER, Looman CW. Menstrual cycle length preceding menopause in relation to age at menopause. Maturitas. 1998;29:115-123.
99. Treloar AE, Boynton RE, Behn BG, Brown BW. Variation of the human menstrual cycle through reproductive life. Int J Fertil. 1970;12:77-126.
100. Treloar AE. Menstrual cyclicity and the pre-menopause. Maturitas. 1981;3:249-264.
101. Cooper GS, Baird DD, Darden FR. Measures of menopausal status in relation to demographic, reproductive, and behavioral characteristics in a population-based study of women aged 35-49 years. Am J Epidemiol. 2001;153:1159-1165.
102. Avis NE, Brambilla D, McKinlay SM, Vass K. A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women's Health Study. Ann Epidemiol. 1994;4:214-220.
103. Kaufert PA, Gilbert P, Tate R. The Manitoba Project: a re-examination of the link between menopause and depression. Maturitas. 1992;14:157-160.
104. Matthews KA, Wing RR, Kuller LJ, Meilahn EN, Kelsey SF. Influences of natural menopause on psychological characteristics and symptoms of middle-aged healthy women. J Consult Clin Psychol. 1990;48:345-351.
105. Nicol-Smith L. Causality, menopause and depression: a critical review of the literature. BMJ. 1996;313:1229-1232.
106. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the national comorbidity survey. Am J Psychiatry. 1994;151:979-986.
107. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the national comorbidity survey. I: lifetime prevalence, chronicity and recurrence. J Affect Disord. 1993;29:85-96.
108. Roberts RE, Vernon SW. The center for epidemiologic studies depression scale: its use in a community sample. Am J Psychiatry. 1983;140:41-46.
109. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry. 1992;49:809-816.
110. Avis NE, Stellato R, Crawford S, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med. 2001;52:345-356.
111. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000;96:351-358.
112. Bosworth HB, Bastian LA, Kuchibhatla MN, et al. Depressive symptoms, menopausal status, and climacteric symptoms in women at midlife. Psychom Med. 2001;63:603-608.
113. Soares CN, Almeida OP. Depression during the perimenopause. Arch Gen Psychiatry. 2001;58:306.
114. Whooley MA, Grady D, Cauley JA. Postmenopausal estrogen therapy and depressive symptoms in older women. J Gen Intern Med. 2000;15:535-541.
115. Carranza-Lira S, Valentino-Figueroa ML. Estrogen therapy for depression in postmenopausal women. Int J Gynaecol Obstet. 1999;64:35-38.
116. Zweifel JE, O'Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology. 1997;22:189-212.
117. Palinkas LA, Barrett-Connor E. Estrogen use and depressive symptoms in postmenopausal women. Obstet Gynecol. 1992;80:30-36.
118. Ditkoff EC, Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol. 1991;78:991-995.
119. Saletu B, Brandstatter N, Metka M, et al. Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression. Psychopharmacology (Berl). 1995;122:321-329.
120. Coope J. Is oestrogen therapy effective in the treatment of menopausal depression? J R Coll Gen Pract. 1981;31:134-140.
121. Strickler RC, Borth R, Cecutti A, et al. The role of oestrogen replacement in the climacteric syndrome. Psychol Med. 1977;7:631-639.
122. Thomson J, Oswald I. Effect of oestrogen on the sleep, mood, and anxiety of menopausal women. BMJ. 1977;2:1317-1319.
123. Burt VK, Altshuler LL, Rasgon N. Depressive symptoms in the perimenopause: prevalence, assessment, and guidelines for treatment. Harvard Rev Psychiatry. 1998;6:121-132.
124. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol. 1977;4:31-47.
125. Schneider MA, Brotherton PL, Hailes J. The effect of exogenous oestrogens on depression in menopausal women. Arch Gen Psychiatry. 1977;2:162-163.
126. Klaiber EL, Broverman DM, Vogel W, Kobayashi Y. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry. 1979;36:550-554.
127. Furuhjelm M, Karlgren E, Carlström K. The effect of estrogen therapy on somatic and psychical symptoms in postmenopausal women. Acta Obstet Gynecol Scand. 1984;63:655-661.
128. Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58:529-534.
129. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol. 2000;183:414-420.
130. Blümel JE, Castelo-Branco C, Binfa L, Aparicio R, Mamani L. A scheme of combined oral contraceptives for women more than 40 years old. Menopause. 2001;8:286-289.
131. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157:1445-1452.
132. Martenyi F, Dossenbach M, Mraz K, Metcalfe S. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 2001;11:227-232.
133. Schneider LS, Small GW, Hamilton SH, Bystritaky A, Nemeroff CB, Meyers BS. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Am J Geriatr Psychiatry. 1997;5:97-106
134. Schneider LS, Small GW, Clary CM. Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. Am J Geriatr Psychiatry. 2001;9:393-399.
135. Amsterdam J, Garcia-Espana F, Fawcett J, et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord. 1999;55:11-17.
136. Speroff L, Glass RH, Kase NG. Clinical Gynecologic Endocrinology and Infertility. 6th ed. Baltimore, Md: Lippincott Williams & Wilkins; 1999.
137. Kaunitz AM. Oral contraceptive use in perimenopause. Am J Obstet Gynecol. 2001;185:S32-S37.
138. Rannevik G, Jeppsson S, Johnell O, Bjerre B, Laurell-Borulf Y, Svanberg L. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas. 1995;21:103-113.
139. Burger HG, Dudley EC, Hopper JL, et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab. 1999;84:4025-4030.
140. O'Hara MW, Neunaber DJ, Zekowski EM, Prospective study of postpartum depression: prevalence, course, and predictive factors. J Abnorm Psychol. 1984;93:158-171.
141. Georgiopoulos AM, Bryan TL, Wollan P, Yawn BP. Routine screening for postpartum depression. J Fam Pract. 2001;50:117-122.
142. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry. 1987;150:662-673.
143. Pop VJM, Essed GGM, DeGeus CA, van Son MM, Komproe IH. Prevalence of post partum depression - or is it post-puerperium depression? Acta Obstet Gynecol Scand. 1993:72;354-358.
144. Evans J, Heron J, Francomb H, Oke S, Golding J. Cohort study of depressed mood during pregnancy and after childbirth. BMJ. 2001;323:257-260.
145. Josefsson A, Berg G, Nordin C, Sydsjo G. Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet Gynecol Scand. 2001;80:251-255.
146. Affonso DD, Mayberry LJ, Lovett S, et al. Pregnancy and postpartum depressive symptoms. J Women's Health. 1993;2:157-164.
147. Pearlstein TB, Frank E, Rivera-Tovar A, Thoft JS, Jacobs E, Mieczkowski TA. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord. 1990;20:129-134.
148. Chuong CJ, Burgos DM. Medical history in women with premenstrual syndrome. J Psychosom Obstet Gynaecol. 1995;16:21-27.
149. Jermain DM. Psychopharmacologic approach to postpartum depression. J Women's Health. 1992;1:47-52.
150. Appleby L, Warner R, Whitton A, et al. A controlled study of fluoxetine and cognitive-behavioral counseling in the treatment of postnatal depression. BMJ. 1997;314:932-936.
151. Stowe ZN, Casarella J, Landry J, et al. Sertraline in the treatment of women with postpartum major depression. Depression. 1995;3:49-55.
152. Cohen LS, Viguera AC, Bouffard SM, Nonacs RM, Morabito C, Collins Ablon JS. Venlafaxine in the treatment of postpartum depression. J Clin Psychiatry. 2001;62:592-296.
153. Suri R, Burt VK, Altshuler L, Zuckerbrow-Miller J, Fairbanks L. Fluvoxamine for the treatment of postpartum depression. Am J Psychiatry. 2001;158:1739-1740.
154. Hendrick V, Altshuler L, Strouse T, Grosser S. Postpartum and non-postpartum depression: differences in presentation and response to pharmacologic treatment. Depress Anxiety 2000;11:66-72.
155. Newport DJ, Wilcox MM, Stowe ZN. Antidepressants during pregnancy and lactation: defining exposure and treatment issues. Semin Perinatol. 2001;25:177-190.
156. Hendrick V, Stowe ZN, Altshuler LL, et al. Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. Biol Psychiatry. 2001;50:775-782.
157. Hendrick V, Stowe ZN, Altshuler LL, et al. Paroxetine use during breast-feeding. J Clin Psychopharmacol. 2000;20:587-589.
158. Wisner KL, Perel JM, Findling RL. Antidepressant treatment during breast-feeding. Am J Psychiatry. 1996;1S3:1132-1137.
159. Wisner KL, Perel JM, Blumer J. Serum sertraline and N-desmethylsertraline levels in breast-feeding mother-infant pairs. Am J Psychiatry. 1998;155:690-692.
160. Stowe ZN, Cohen LS, Hostetter A, et al. Paroxetine in human breast milk and nursing infants. Am J Psychiatry. 2000;157:185-189.
161. Piontek CM, Wisner KL, Perel JM, Peindl KS. Serum fluvoxamine levels in breastfed infants. J Clin Psychiatry. 2001;62:111-113.
162. Wisner KL, Perel JM, Peindl KS, Hanusa BH, Findling RL, Rapport D. Prevention of recurrent postpartum depression: a randomized clinical trial. J Clin Psychiatry. 2001;62:82-86.
163. Ahokas A, Kaukoranta Jutta, Wahlbeck K, Aito M. Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17β-estradiol: a preliminary study. J Clin Psychiatry. 2001;62:332-336.
164. Ahokas A, Aito M, Rimón R. Positive treatment effect of estradiol in postpartum psychosis: a pilot study. J Clin Psychiatry. 2000;61:166-169.
165. Gregoire AJ, Kumar R, Everitt B, et al. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 1996;347:930-933.
166. Sichel DA, Cohen LS, Robertson LM, et al. Prophylactic estrogen in recurrent postpartum affective disorder. Biol Psychiatry 1995;38:814-818.
167. Epperson CN, Wisner KL, Yamamoto B. Gonadal steroids in the treatment of mood disorders. Psychosom Med. 1999;61:676-697.
168. Granger AC, Underwood MR. Review of the role of progesterone in the management of postnatal mood disorders. J Psychosom Obstet Gynaecol. 2001;22:49-55.
169. Lawrie TA, Hofmeyr GJ, De Jager M, Berk M, Paiker J, Viljoen E. A double-blind randomised placebo-controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. Br J Obstet Gynaecol. 1998;105:1082-1090.
170. O'Hara MW, Stuart S, Gorman LL, Wenzel A. Efficacy of interpersonal psychotherapy for postpartum depression. Arch Gen Psychiatry. 2000;57:1039-1045.
171. Evins GG, Theofrastous JP, Galvin SL. Postpartum depression: a comparison of screening and routine clinical evaluation. Am J Obstet Gynecol. 2000;182:1080-1082.
172. Beck CT. The effects of postpartum depression on child development: a meta-analysis, Arch Psychiatr Nurs. 1998;12:12-20.
173. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 1987;150:782-786.